Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
OX40 ligand expressed by DCs costimulates NKT and CD4+ Th cell antitumor immunity in mice
Jamal Zaini, … , Toshihiro Nukiwa, Toshiaki Kikuchi
Jamal Zaini, … , Toshihiro Nukiwa, Toshiaki Kikuchi
Published November 1, 2007
Citation Information: J Clin Invest. 2007;117(11):3330-3338. https://doi.org/10.1172/JCI32693.
View: Text | PDF
Research Article

OX40 ligand expressed by DCs costimulates NKT and CD4+ Th cell antitumor immunity in mice

  • Text
  • PDF
Abstract

The exceptional immunostimulatory capacity of DCs makes them potential targets for investigation of cancer immunotherapeutics. We show here in mice that TNF-α–stimulated DC maturation was accompanied by increased expression of OX40 ligand (OX40L), the lack of which resulted in an inability of mature DCs to generate cellular antitumor immunity. Furthermore, intratumoral administration of DCs modified to express OX40L suppressed tumor growth through the generation of tumor-specific cytolytic T cell responses, which were mediated by CD4+ T cells and NKT cells. In the tumors treated with OX40L-expressing DCs, the NKT cell population significantly increased and exhibited a substantial level of IFN-γ production essential for antitumor immunity. Additional studies evaluating NKT cell activation status, in terms of IFN-γ production and CD69 expression, indicated that NKT cell activation by DCs presenting α-galactosylceramide in the context of CD1d was potentiated by OX40 expression on NKT cells. These results show a critical role for OX40L on DCs, via binding to OX40 on NKT cells and CD4+ T cells, in the induction of antitumor immunity in tumor-bearing mice.

Authors

Jamal Zaini, Sita Andarini, Minoru Tahara, Yasuo Saijo, Naoto Ishii, Kazuyoshi Kawakami, Masaru Taniguchi, Kazuo Sugamura, Toshihiro Nukiwa, Toshiaki Kikuchi

×

Figure 3

Involvement of NKT cells in the therapeutic effect elicited by intratumoral administration of AdOX40L-modified DCs.

Options: View larger image (or click on image) Download as PowerPoint
Involvement of NKT cells in the therapeutic effect elicited by intratumo...
(A) Immunohistochemical evaluation of tumors for OX40+ cells. Three days after injection of AdOX40L- or AdNull-modified DCs to B16-F10 tumors, frozen sections of the tumors were stained with anti-mouse OX40 antibody. Numbers at bottom right denote the number of positive cells per 10 random high-power fields (original magnification, ×400). Untreated tumors were used as controls. (B) OX40+CD1d/α-GalCer dimer+ cells. OX40+ cells from tumors treated with AdOX40L-modified DCs were analyzed for the CD1d/α-GalCer dimer binding by flow cytometry. Overlay (filled) histogram depicts OX40+ cells stained without dimer. The percentage of CD1d/α-GalCer dimer+ cells above control staining is shown. (C) Quantification of intratumoral NKT cells. The number of CD1d/α-GalCer dimer+ NKT cells in tumors treated as in A was determined by flow cytometry. (D and E) Role of NKT cells. NKT cell–/– (circles) or wild-type mice (triangles) bearing B16-F10 tumors were treated with AdOX40L-modified DCs. Tumor-bearing wild-type mice without any treatment (squares) were used as controls. (F and G) Role of OX40 on NKT cells. The NKT cell–/– mice were reconstituted with OX40–/– (circles) or wild-type NKT cells (triangles) 1 day before the treatment. (H and I) Role of CD1d on DCs. CD1d–/– (circles) or wild-type DCs (triangles) were used to prepare AdOX40L-modified DCs for the treatment. (D, F, and H) The size of each tumor was assessed to evaluate tumor growth. (E, G, and I) At 10 days after treatment, splenocytes were isolated and assayed for cytolytic function using B16-F10 or LLC cells as target cells.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts